Ken Griffin Compugen LTD Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Compugen LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 17,600 shares of CGEN stock, worth $33,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,600

Previous 13,400 31.34%

Holding current value

$33,440

Previous $34,000 14.71%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.68 - $2.52 $174,432 - $261,649	-103,829 Reduced 99.27%	764 $1,000
Q1 2024 May 15, 2024	BUY	$1.75 - $2.95 $148,137 - $249,717	84,650 Added 424.46%	104,593 $269,000
Q4 2023 Feb 14, 2024	BUY	$0.53 - $2.0 $10,569 - $39,886	19,943 New	19,943 $39,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.38 $1,460 - $3,536	2,563 New	2,563 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.58 - $1.2 $510 - $1,057	-881 Reduced 0.41%	215,367 $155,000
Q3 2022 Nov 14, 2022	BUY	$0.66 - $2.32 $63,310 - $222,545	95,925 Added 79.72%	216,248 $142,000
Q2 2022 Aug 15, 2022	SELL	$1.57 - $3.33 $170,549 - $361,737	-108,630 Reduced 47.45%	120,323 $223,000
Q1 2022 May 16, 2022	SELL	$2.76 - $4.64 $148,780 - $250,123	-53,906 Reduced 19.06%	228,953 $737,000
Q4 2021 Feb 14, 2022	SELL	$4.09 - $7.16 $1.85 Million - $3.24 Million	-452,273 Reduced 61.52%	282,859 $1.22 Million
Q3 2021 Nov 15, 2021	BUY	$5.8 - $8.02 $1.06 Million - $1.46 Million	182,513 Added 33.03%	735,132 $4.39 Million
Q2 2021 Aug 16, 2021	BUY	$6.87 - $9.16 $2.28 Million - $3.03 Million	331,307 Added 149.7%	552,619 $4.58 Million
Q1 2021 May 17, 2021	SELL	$7.67 - $13.77 $432,925 - $777,233	-56,444 Reduced 20.32%	221,312 $1.9 Million
Q4 2020 Feb 16, 2021	BUY	$12.07 - $17.95 $1.82 Million - $2.71 Million	150,962 Added 119.06%	277,756 $3.36 Million
Q3 2020 Nov 16, 2020	SELL	$14.16 - $19.45 $744,830 - $1.02 Million	-52,601 Reduced 29.32%	126,794 $2.06 Million
Q2 2020 Aug 14, 2020	SELL	$6.97 - $17.12 $4.22 Million - $10.4 Million	-606,104 Reduced 77.16%	179,395 $2.7 Million
Q1 2020 May 15, 2020	BUY	$5.79 - $11.83 $4.47 Million - $9.13 Million	771,571 Added 5539.71%	785,499 $5.7 Million
Q2 2019 Aug 14, 2019	SELL	$2.8 - $4.14 $4,062 - $6,007	-1,451 Reduced 9.43%	13,928 $53,000
Q1 2019 May 15, 2019	SELL	$2.35 - $4.19 $60,968 - $108,705	-25,944 Reduced 62.78%	15,379 $0
Q4 2018 Feb 14, 2019	BUY	$2.17 - $3.8 $54,662 - $95,722	25,190 Added 156.14%	41,323 $89,000
Q3 2018 Nov 13, 2018	SELL	$3.0 - $4.05 $1,743 - $2,353	-581 Reduced 3.48%	16,133 $0
Q1 2018 May 11, 2018	SELL	$2.5 - $4.45 $9,122 - $16,238	-3,649 Reduced 17.92%	16,714 $74,000
Q4 2017 Feb 09, 2018	BUY	$2.35 - $4.0 $47,853 - $81,452	20,363	20,363 $51,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.4M

Call Options Held

191K

Put Options Held

135K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $165M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account